Shingles vaccine schedules for MS and NMOSD on anti-CD20 therapy
Part of Brain & nervous system, Immune system & allergy, Infections clinical trials.
This study compares two ways of giving the shingles vaccine to people with MS or NMOSD who are on anti-CD20 treatments like Ocrelizumab or Rituximab. The goal is to see which schedule gives better protection against shingles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MS (any form) or NMOSD with positive AQP4 antibodies
- You are 18 or older
- You are currently on Ocrelizumab or Rituximab (not Ofatumumab) and have been for less than 2 years
- You have had chickenpox or shingles in the past (or a positive blood test for the virus)
- You have not had shingles in the last 12 months and no shingles vaccine in the last 5 years
- You have not had high-dose steroids (e.g., methylprednisolone) in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new shingles vaccine (called an mRNA vaccine) given as a shot. It aims to prevent shingles in adults aged 40 and above. If you qualify, you may receive the vaccine or a placebo, and your health will be monitored for a period of time.
This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.
This study tests the recombinant shingles vaccine in adults with autoimmune rheumatic diseases who are on certain mild medications. It aims to see if the vaccine is safe and effective for them.
This trial tests a new shingles vaccine for healthy adults 40 and older. It aims to see if the vaccine is safe and helps protect against shingles.
This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.